SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Nala Santoro

SPECIES
Canine

BREED
Pitbull Terrier

SEX
Female Spayed

AGE
11 years

WEIGHT
95.2lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Kelly Vazquez, CVT

HOSPITAL NAME
Animal General on Hudson

REFERRING VET
Dr. Zelinksi

INVOICE
28728

DATE
2/1/23

PRESENTING CLINICAL SIGNS

History: Lung mass. Assess prior to anesthesia for FNA.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Moderate left ventricular dilation with decreased systolic function and increased sphericity. Decreased LV wall thickness. Increased EPSS. Severe left atrial enlargement. The mitral valve appears thickened with no prolapse and moderate mitral regurgitation. The MR velocity is normal. The tricuspid valve appears normal in form and function. Mild right atrial and ventricular dilation. Mild to moderate tricuspid regurgitation. Normal velocity. The aortic valve is normal in morphology and mobility. No subvalvular ridge present; normal LVOT velocity. No aortic insufficiency. Normal pulmonic valve with no pulmonic insufficiency seen. Normal RVOT velocity. No pericardial or pleural effusion noted. No obvious cardiac tumors.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.8	2.0	NM	2.3	18	30	NM
CANINE CARDIAC PARAMETERS	**HR** (BPM)	**AV VMAX** (m/s)	**PV MAX** (m/s)	**BODY WEIGHT** (kg)	**LA** 2D short axis Base view (cm)	**LVIDd** Avg; 2D and m-mode short axis (cm)	**LVIDs** Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	125	NM	1.1	43.2	4.6	6.5	5.3
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
**Note: All measurements based upon multi-modal images and methods. An average value is reported.*				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
Adapted from June Boon, Veterinary Echocardiography, 1998				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
Hansson et al, Vet Rad and Ultrasound 2002				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Unfortunately, this patient has significant cardiomyopathy and systolic dysfunction. There is dilation and volume overload of both the left and right heart. A concurrent valvular issue may be at play given moderate MR. Regardless, the severity of dysfunction and pump failure is significant and the patient is at high risk for decompensating into congestive failure. Patient will always be at risk for right and/or left-sided CHF, development of arrhythmias/syncope and/or sudden death going forward.



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Nala Santoro

SPECIES
Canine

BREED
Pitbull Terrier

SEX
Female Spayed

AGE
11 years

WEIGHT
95.2lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Kelly Vazquez, CVT

HOSPITAL NAME
Animal General on Hudson

REFERRING VET
Dr. Zelinksi

INVOICE
28728

DATE
2/1/23

Systolic failure can be primary in nature (DCM) or secondary to taurine deficiency, myocarditis, tachycardia-induced cardiomyopathy, or infiltrative disease such as lymphoma. In a senior Pitbull, primary disease is certainly possible; however, consider testing for alternative causes that may be treatable. A troponin (cTnI) level can be submitted to further investigate infiltrative/inflammatory contribution (myocarditis). Additionally, a taurine level may be helpful (screen for malabsorption issue), and a thorough diet history given the recent correlation with grain free/boutique brand/exotic ingredient diets. Finally, further systemic evaluation for underlying infiltrative contribution such as neoplasia is also reasonable (abdominal ultrasound, etc.). Regardless of cause, prognosis is guarded to poor at this stage in the disease process, with an average survival time of <6 months. The only treatable cause of systolic failure is diet/taurine deficiency, which is uncommon on commercially formulated dog foods. If the diet is of concern, highly recommend immediate diet change and taurine supplement regardless of blood taurine results. Please see the FDA website for more information.

Immediate institution of full cardiac supportive medications is recommended as below due to exceedingly high risk for decompensation. Cases of systolic failure are at high risk for malignant tachyarrhythmias (such as VT or rapid AF) and sudden death, and this should be expressed to the owner. Activity restriction is advised.

Elective anesthesia is not advised. Heavy sedation may be reasonable if able to be performed utilizing cardiac-protective options, such as Butorphanol, Alfaxalone or Propofol. Close monitoring throughout the procedure is strongly recommended.

Omega fatty acid supplementation and mild salt restriction may be of some long-term benefit. Monitor for development of a cough, worsening labored breathing, abdominal distention, exercise intolerance or collapse episodes in the future. Monitoring of sleeping breathing rates at home is recommended to assess response to medications and recurrence of CHF in the future.

PLAN:
Baseline BP/ECG are recommended. Initiate aldosterone antagonist Spironolactone 1-2mg/kg PO q12h. Institute furosemide 1mg/kg PO q12h. Institute Pimobendan 0.3mg/kg PO q12h. Institute taurine 1000mg PO q12h. Diet history/change as discussed.

Monitor a renal panel and blood pressure in 1-2 weeks to ensure tolerance. If BP >130mmHg, institute ACEI 0.5mg/kg PO q12h. Consider cTnI, taurine level, AUS as discussed above.

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical issues arise in the interim.

SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Nala Santoro

SPECIES
Canine

BREED
Pitbull Terrier

SEX
Female Spayed

AGE
11 years

WEIGHT
95.2lbs

INTERPRETED BY
Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY
Kelly Vazquez, CVT

HOSPITAL NAME
Animal General on Hudson

REFERRING VET
Dr. Zelinksi

INVOICE
28728

DATE
2/1/23

IMAGES







The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com